In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discuss the findings from cohort 5 of the ZENITH20 study including the strategy of splitting the dose in half to reduce adverse events associated with poziotinib.
In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.
Adding tislelizumab to chemotherapy improved overall survival and progression-free survival in patients with extensive-stage small cell lung cancer, according to findings from a phase 3…
Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.
A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and…
During a Case-Based Roundtable® event, John Mascarenhas, MD, discussed the efficacy data behind the use of pacritinib in patients with myelofibrosis in the first article…
In an interview with Targeted Oncology, David L. Bartlett, MD, discussed the utilization and growing importance of genomic testing in cancer care.
The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a…
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with…
Dr. Schiller will discuss how their treatment approach would differ for a 74-year-old BPDCN patient with only well-controlled type 2 diabetes as a comorbidity and…
